Gender-dependent association of type 2 diabetes with the vasoactive intestinal peptide receptor 1

Gene

Volumn 493, Issue 2, 2012, Pages 278-281

  Paladini, Fabiana ^a   Adinolfi, Valerio ^a   Cocco, Elisa ^a   Ciociola, Ester ^a   Tamburrano, Giulia ^a   Cascino, Isabella ^b   Lucantoni, Federica ^a   Morano, Susanna ^a   Sorrentino, Rosa ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CNR   (Italy)

Author keywords

Inflammation; Lipid metabolism; Type 2 diabetes; Vasoactive Intestinal peptide

Indexed keywords

CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENDER; GENETIC ANALYSIS; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; RISK; SINGLE NUCLEOTIDE POLYMORPHISM;

CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; SEX CHARACTERISTICS; SIGNAL TRANSDUCTION;

EID: 84855825077     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2011.11.055     Document Type: Article

References (20)

1. Cocco E., Paladini F., Macino G., Fulci V., Fiorillo M.T., Sorrentino R. The expression of vasoactive intestinal peptide receptor 1 is negatively modulated by microRNA 525-5p. PLoS One 2010, 5:e12067.
2. Delgado M., et al. Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells. Arthritis Rheum. 2008, 58:1010-1019.
3. Dickson L., Finlayson K. VPAC and PAC receptors: from ligands to function. Pharmacol. Ther. 2009, 121:294-316.
4. Donath M.Y., Shoelsen S.E. type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 2011, 11:98-107.
5. Gonzalez-Rey E., Varela N., Chorny A., Delgado M. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. Curr. Pharm. Des. 2007, 13:1113-1139.
6. Ihaka R., Gentleman R.R. A language for data analysis and graphics. J. Comput. Graph. Stat. 1996, 5:299-314.
7. Kahn S.E., Hull R.L., Utzscheneder K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444:840-846.
8. Kato I., et al. Transgenic mice overexpressing human vasoactive intestinal peptide (VIP) gene in pancreatic beta cells. Evidence for improved glucose tolerance and enhanced insulin secretion by VIP and PHM-27 in vivo. J. Biol. Chem. 1994, 269:21223-21228.
9. Kautzky-Willer A., et al. Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus. Gend. Med. 2010, 7:571-583.
10. Liu Y.J., et al. Biological pathway-based genome-wide association analysis identified the vasoactive intestinal peptide (VIP) pathway important for obesity. Obesity (Silver Spring) 2010, 18:2339-2346.
11. Martin B., et al. Vasoactive intestinal peptide-null mice demonstrate enhanced sweet taste preference, dysglycemia, and reduced taste bud leptin receptor expression. Diabetes 2010, 59:1143-1152.
12. McCarthy M.I. Genomics, type 2 diabetes and obesity. N. Engl. J. Med. 2010, 363:2339-2350.
13. Moody T.W., Ito T., Osefo N., Jensen R.T. VIP and PACAP: recent insights into their function/roles in physiology and disease from molecular and genetic studies. Curr. Opin. Endocrinol. Diabetes Obes. 2011, 18:1861-1867.
14. Mooradian A.D. Dyslipidemia in type 2 diabetes mellitus. Nat. Clin. Pract. Endocrinol. Metab. 2009, 5:150-159.
15. Nakhjavani M., Morteza A., Esteghamati A., Khalilzadeh O., Zandieh A., Safari R. Serum lipoprotein(a) levels are greater in female than male patients with type 2 diabetes. Lipids 2011, 46:349-356.
16. Njajou O.T., et al. Association between oxidized LDL, obesity and type 2 diabetes in a population-based cohort, the Health, Aging and Body Composition Study. Diabetes Metab. Res. Rev. 2009, 25:733-739.
17. Paladini F., et al. A functional polymorphism of the vasoactive intestinal peptide receptor 1 gene correlates with the presence of HLA-B*2705 in Sardinia. Genes Immun. 2008, 9:659-667.
18. Voight B.F., et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat. Genet. 2010, 42:579-589.
19. Wannamethee S.G., et al. Do woman exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women's Heart Health Study. Diabetologia 2011, (Aug 23, Epub ahead of print).
20. Winzell M.S., Ahrén B. Role of VIP and PACAP in islet function. Peptides 2007, 28:1805-1813.